Compounds > l-pyroglutamyl-l-histidyl-3,3-dimethylprolinamide
Page last updated: 2024-09-02

l-pyroglutamyl-l-histidyl-3,3-dimethylprolinamide and vasoactive intestinal peptide

l-pyroglutamyl-l-histidyl-3,3-dimethylprolinamide has been researched along with vasoactive intestinal peptide in 1 studies

Compound Research Comparison

Studies
(l-pyroglutamyl-l-histidyl-3,3-dimethylprolinamide)		Trials
(l-pyroglutamyl-l-histidyl-3,3-dimethylprolinamide)		Recent Studies (post-2010)
(l-pyroglutamyl-l-histidyl-3,3-dimethylprolinamide)		Studies
(vasoactive intestinal peptide)		Trials
(vasoactive intestinal peptide)		Recent Studies (post-2010) (vasoactive intestinal peptide)
1387210,8731231,221

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Guth, P; Király, A; Sütó, G; Taché, Y1

Other Studies

1 other study(ies) available for l-pyroglutamyl-l-histidyl-3,3-dimethylprolinamide and vasoactive intestinal peptide

ArticleYear
Influence of [4Cl-D-Phe6,Leu17]VIP on VIP- and central TRH-induced gastric hyperemia.
    Peptides, 1997, Volume: 18, Issue:9

    Topics: Animals; Cisterna Magna; Efferent Pathways; Gastric Mucosa; Hyperemia; Male; Microinjections; Pyrrolidonecarboxylic Acid; Rats; Rats, Sprague-Dawley; Regional Blood Flow; Stomach Diseases; Thyrotropin-Releasing Hormone; Vagus Nerve; Vasoactive Intestinal Peptide

1997